BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

GlaxoSmithKline (GSK) Pays $150 Million to Settle Flonase Antitrust Lawsuit


6/21/2013 7:27:01 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

GlaxoSmithKline can pay $150 million to settle claims that it inflated the Flonase prices and delayed the release of a generic nasal spray, a federal judge ruled. American Sales Co. Inc., a Lancaster, N.Y.-based distributor of health and beauty items and general merchandise for U.S. supermarkets, had filed the suit with regional hypermarket chain Meijer Inc. and its distribution company, headquartered in Walker, Mich. Their 2008 class action sought to represent 33 companies that purchase Flonase and its generic counterpart directly from the manufacturers: SmithKline Beecham dba GlaxoSmithKline and Roxane Laboratories. They claimed that GSK improperly delayed the entry of the less expensive, generic fluticasone propionate to rake in multimillion-dollar profits. The delay allegedly let GSK maintain the price of the brand-name drug at above-competitive levels and block unrestricted competition. Extensive discovery, which lasted from late 2008 through mid-2010, included 30 depositions of current and former GSK and Roxane employees and millions of pages of documents, including at least a dozen expert reports and rebuttals.

Help employers find you! Check out all the jobs and post your resume.


Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->